|
Stallergenes - Comparative Business Analysis Snapshot
Business Description
Stallergenes. The Group's principal activity is to develop, produce and distribute immunotherapy solutions to treat allergies. The Group offers allergen extracts used to correct the immune imbalance. The Group supplies therapeutic products for diagnostic purpose as well as treatments. Under diagnostic purpose, the Group offers prick tests and vitro tests which help medical professionals to confirm the diagnosis. Under treatments, the Group offers subcutaneous injections, and sublingual drops. The Group operates mainly in France, Spain, Portugal, Italy, Greece and Switzerland.
Competitor Analysis
This analysis compares Stallergenes with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
